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Abstract
Objectives: The aim of this study is to investigate if correlations exist between income inequality and antimicrobial
resistance. This study’s hypothesis is that income inequality at the national level is positively correlated with
antimicrobial resistance within developed countries.
Data collection and analysis: Income inequality data were obtained from the Standardized World Income Inequality
Database. Antimicrobial resistance data were obtained from the European antimicrobial Resistance Surveillance
Network and outpatient antimicrobial consumption data, measured by Defined daily Doses per 1000 inhabitants per
day, from the European Surveillance of antimicrobial Consumption group. Spearman’s correlation coefficient (r)
defined strengths of correlations of: > 0.8 as strong, > 0.5 as moderate and > 0.2 as weak. Confidence intervals and
p values were defined for all r values. Correlations were calculated for the time period 2003-10, for 15 European
countries.
Results: Income inequality and antimicrobial resistance correlations which were moderate or strong, with 95%
confidence intervals > 0, included the following. Enterococcus faecalis resistance to aminopenicillins, vancomycin
and high level gentamicin was moderately associated with income inequality (r= ≥0.54 for all three antimicrobials).
Escherichia coli resistance to aminoglycosides, aminopenicillins, third generation cephalosporins and
fluoroquinolones was moderately-strongly associated with income inequality (r= ≥0.7 for all four antimicrobials).
Klebsiella pneumoniae resistance to third generation cephalosporins, aminoglycosides and fluoroquinolones was
moderately associated with income inequality (r= ≥0.5 for all three antimicrobials). Staphylococcus aureus methicillin
resistance and income inequality were strongly associated (r=0.87).
Conclusion: As income inequality increases in European countries so do the rates of antimicrobial resistance for
bacteria including E. faecalis, E. coli, K. pneumoniae and S. aureus. Further studies are needed to confirm these
findings outside Europe and investigate the processes that could causally link income inequality and antimicrobial
resistance.
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Introduction
Antimicrobial therapy has contributed greatly to
improvements in human health care through the treatment of
infectious diseases. Unfortunately, an increase in
antimicrobially resistant microorganisms threatens to limit the
effectiveness of antimicrobial therapy, and therefore the
benefits derived from these drugs [1]. For example, the
European Centre for Disease Control recently estimated that
25,000 deaths per year within Europe are directly related to
antibiotic resistance [2].
Rates of antimicrobial resistance vary significantly between
countries. These variations have been well documented and
have been principally related to antimicrobial consumption, i.e.
the more antibiotics a country consumes the more resistance is
likely to result [3]. However there is limited research to fully
explain why resistance rates vary between countries. One area
that has yet to be researched is the impact of a nation’s
economic policy on antimicrobial consumption and the
development of antimicrobial resistance [4]. A nation’s
economic policy determines many outcomes within the
societies they impact on, including that country’s income
inequality. Income inequality is the difference in incomes
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between those with the highest and lowest incomes in society.
Income inequality at the national level has been proposed as
being the underlying cause of numerous undesired outcomes
in developed countries, e.g. homicide rates, and particularly
undesired health care outcomes [5]. Wilkinson and Pickett
have shown that higher rates of diabetes and mental illness
(including drug and alcohol addiction) are associated with
higher levels of income inequality at the national level [5],
within developed countries (data from developing countries are
unavailable to make similar comparisons). This raises the
question of whether income inequality is associated with
infection-related health care outcomes, such as antimicrobial
resistance. A causative mechanism might be, for example, that
with increased levels of disease, e.g. diabetes, there may be a
corresponding increase in infections e.g. diabetic foot
infections. This could result in more antimicrobial prescribing, in
turn associated with higher rates of antimicrobial resistance [3].
This study therefore investigated the associations between
income inequality, antimicrobial resistance and antimicrobial
consumption within developed countries, via calculation of
correlation coefficients between these variables.
Methods
Income inequality, antimicrobial resistance and antimicrobial
consumption were correlated with each other. The analyses
were completed on European countries over an eight year time
period, 2003-10.
Income inequality data
Data were taken from the Standardized World Income
Inequality Database (SWIID) [6]. The SWIID provides
estimates of income inequality within a country which is
suitable for broad cross-national analyses. The higher the
SWIID score the greater a country’s income inequality.
Antimicrobial resistance
Data were taken from the European Antimicrobial Resistance
Surveillance Network (EARS-Net) [7]. Countries report on the
susceptibility of isolates derived from blood cultures and
cerebrospinal fluids only. They report data for Enterococcus
faecalis, Enterococcus faecium, Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa, Staphylococcus
aureus and Streptococcus pneumoniae.
Antimicrobial consumption
Data were taken from the European Surveillance of
Antimicrobial Consumption (ESAC) group [8]. ESAC provide
data on the defined daily doses (DDD) of antibiotic
consumption per inhabitant per 1000 days (DID). DDD is the
assumed average maintenance dose per day for a drug used
for its main indication in adults, as defined by the World Health
Organization [9]. Total antimicrobial consumption data (all
antimicrobial classes combined) from outpatients were
extracted for the period 2003-2009; consumption data for 2010
data were unavailable. It was not possible to compare a
specific antibiotic’s consumption to its correlated resistance as
the ESAC data do not correspond directly with the EARSnet
data e.g. ESAC reports on penicillin consumption but not on
aminopenicillins consumption specifically [10]. Insufficient
hospital consumption data from these periods were available
for analysis.
Country and year selection
Only European countries were included in the study as only
these countries had comparable antimicrobial resistance data.
Countries were selected from the richest 50 (by Gross National
Income per capita at purchasing power parities) in 2002.
Countries with a population of less than 3 million were
excluded to avoid inclusion of tax havens [5]. The following 15
countries were therefore included in the study: Austria,
Belgium, Denmark, Finland, France, Germany, Greece,
Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden
and the United Kingdom. Data were analysed from 2003–2010
as EARSnet data are relatively limited before 2003.
Statistical analysis
Within each antibiotic group, Spearman’s rank order
correlation coefficient (r) was calculated per year between
income inequality (SWIID) and percentage resistance. Pooled
correlations for each antibiotic group were calculated from
individual year correlations within this group via the Schmidt-
Hunter method [11], as well as their confidence intervals (CIs)
and an associated p-value. The Schmidt-Hunter method under-
estimates the correlation when it is greater than 0.5 and
therefore provides a conservative estimate. Where r values are
> 0.8, they are classed as strong, > 0.5 moderate, > 0.2 weak
and 0 as no association [12]. The CI is given as a range of
values which is likely to contain the probable correlation in the
general population; a CI not containing 0 indicates sufficient
evidence that there is a real correlation in the data. The p-value
states how much weight of evidence there is for the observed
data, when the true correlation in the population is 0; the
smaller the p-value, the more likely a real correlation. These
methods were repeated to provide pooled correlations between
income inequality and antimicrobial consumption and
antimicrobial consumption and antimicrobial resistance. EARS-
Net data was incomplete, not every country reported resistance
data for all pathogen-resistance combinations every year of the
study. Therefore pooled correlations of antimicrobial
consumption and antimicrobial resistance were calculated for
the subset in which these data were available.
Scatter plots of resistance vs. income inequality by country
and year were created for a selection of the antimicrobial
resistance and income inequality correlations, with lines of best
fit given, per year. Data were initially compiled using Microsoft
Excel and were analysed using Stata/IC version 11 and
StatsDirect version 3. Graphs were created in Stata/IC version
11.
Results
Correlations between income inequality, antimicrobial
resistance and antimicrobial consumption within European
countries are given below, and in Tables 1 and 2.
Income Inequality and Antimicrobial Resistance
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Income inequality and Enterococcal resistance
E. faecalis resistance to aminopenicillins was moderately
associated with income inequality, r=0.54, 95% confidence
interval (CI) 0.49 to 0.6. It was also moderately associated with
vancomycin resistance, 0.73, 0.68 to 0.79 (Figure 1) and high
level gentamicin resistance, 0.62, 0.55 to 0.69. E. faecium
vancomycin resistance was moderately associated with income
inequality, 0.72, 0.64 to 0.80. E. faecium resistance to high
level gentamicin and aminopenicillins was weakly associated
with income inequality, 0.38, 0.17 to 0.58 and 0.26, 0.06 to
0.44 respectively.
Income inequality and E. coli resistance
E. coli resistance to aminoglycosides was strongly
associated with income inequality, r=0.84, 95% CI: 0.80 to
0.88. Resistance to aminopenicillins, fluoroquinolones and 3rd
generation cephalosporins (Figure 2) was moderately
associated with income inequality, 0.73, 0.70 to 0.77; 0.71, 0.6
to 0.82 and 0.7, 0.68 to 0.73 respectively. Resistance to
carbapenems was weakly associated with income inequality,
0.34, 0.18 to 0.49.
Income inequality and K. pneumoniae resistance
K. pneumoniae resistance to aminoglycosides, third
generation cephalosporins and fluoroquinolones (Figure 3) was
moderately associated with income inequality, r=0.50, 95% CI:
0.42 to 0.57; 0.57, 0.54 to 0.60 and 0.50, 0.42 to 0.57
respectively. Carbapenem resistance was weakly associated
with income inequality, 0.33, 0.29 to 0.37.
Income inequality and P. aeruginosa resistance
P. aeruginosa aminoglycoside, carbapenem, ceftazidime and
fluoroquinolone resistance was moderately associated with
income inequality, r=0.51, 95% CI: 0.47 to 0.56; 0.50, 0.45 to
0.55; 0.51, 0.47 to 0.55 and 0.53, 0.48 to 0.58 respectively.
Piperacillin-tazobactam and amikacin resistance were weakly
associated with income inequality, 0.46, 0.37 to 0.55 and 0.21,
0.15 to 0.26 respectively.
Income inequality and S. aureus resistance data
S. aureus methicillin resistance and income inequality were
strongly associated, r=0.86, 95% CI: 0.83 to 0.89 (Figure 4). S.
Table 1. Antimicrobial resistance associated with income inequality.
Bacterial species Antibiotic group
No. years with data
available





E. faecalis Aminopenicillins 8 13-15 0.54 0.49 to 0.60 <0.0001
 High level gentamicin 8 13-15 0.62 0.55 to 0.69 <0.0001
 Vancomycin 8 13-15 0.73 0.68 to 0.79 <0.0001
E. faecium Aminopenicillins 8 13-15 0.26 0.06 to 0.44 0.012
 High level gentamicin 8 13-15 0.38 0.17 to 0.58 <0.0001
 Vancomycin 8 13-15 0.72 0.64 to 0.80 <0.0001
E. coli Aminoglycosides 8 14-15 0.84 0.80 to 0.88 <0.0001
 Aminopenicillins 8 14-15 0.73 0.70 to 0.77 <0.0001




8 14-15 0.70 0.68 to 0.73 <0.0001
 Fluoroquinolones 8 14-15 0.71 0.60 to 0.82 <0.0001
K. pneumoniae Aminoglycosides 6 13-15 0.50 0.42 to 0.57 <0.0001




6 12-15 0.57 0.54 to 0.60 <0.0001
 Fluoroquinolones 6 13-15 0.50 0.42 to 0.57 <0.0001
P. aeruginosa Amikacin 6 9-11 0.21 0.15 to 0.26 <0.0001
 Aminoglycosides 6 11-15 0.51 0.47 to 0.56 <0.0001
 Carbapenems 6 11-15 0.50 0.45 to 0.55 <0.0001
 Ceftazidime 6 11-15 0.51 0.47 to 0.55 <0.0001




6 11-15 0.46 0.37 to 0.55 <0.0001
S. aureus Methicillin 8 15 0.86 0.83 to 0.89 <0.0001
 Rifampicin 8 10-13 0.56 0.52 to 0.60 <0.0001
S. pneumoniae Penicillin 8 12-14 0.34 0.25 to 0.43 <0.0001
 Macrolides 8 12-14 0.28 0.08 to 0.47 <0.0001
doi: 10.1371/journal.pone.0073115.t001
Income Inequality and Antimicrobial Resistance
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aureus rifampicin resistance was moderately associated with
income inequality, 0.56, 0.52 to 0.60.
Income inequality and S. pneuomoniae:
S. pneumoniae resistance to penicillin and macrolides was
weakly associated with income inequality, r=0.34, 95% CI: 0.25
to 0.43 and 0.28, 0.08 to 0.47.
Income inequality and antimicrobial consumption
Antimicrobial consumption in outpatients measured by
Defined Daily Doses per 1000 inhabitants per day (DID) was
weakly associated with income inequality, r=0.44, 95% CI: 0.41
to 0.48.
Antimicrobial consumption and antimicrobial
resistance
Total antimicrobial consumption in outpatients, measured by
Defined Daily Doses per 1000 inhabitants per day (DID), was
strongly associated with resistance in the following species-
resistance pairings: K. pneumoniae-aminoglycosides, r=0.84,
CI: 0.75 to 0.93, K. pneumoniae-third generation
cephalosporins, 0.85, 0.80 to 0.90, K. pneumoniae-
fluoroquinolones, 0.83, 0.73 to 0.92, P. aeruginosa-amikacin,
0.83,0.73 to 0.92, P. aeruginosa-aminoglycosides, 0.89, 0.87 to
0.92, P. aeruginosa-carbapenems, 0.83, 0.76 to 0.90, P.
aeruginosa-ceftazidime, 0.82, 0.79 to 0.85, P. aeruginosa-
piperacillin-tazobactam, 0.84, 0.78 to 0.90 and S. pneumoniae-
macrolides, 0.86, 0.83 to 0.90. All other bacterial-resistance
pairings analysed were weakly or moderately associated with
antimicrobial consumption except for E. faecium-
aminopenicillins which was not associated with antimicrobial
consumption, -0.06, -0.21 to 0.10 (Table 2).
Discussion
This study showed income inequality to be positively
correlated with antimicrobial resistance in all seven species
analysed: E. faecalis, E. faecium, E. coli, K. pneumoniae, P.
aeruginosa, S. aureus and S. pneumoniae. In addition,
inequality was correlated with antimicrobial consumption, and
antimicrobial consumption was correlated with antimicrobial
resistance.
Table 2. Antimicrobial resistance associated with antimicrobial consumption.
Bacterial species Antibiotic group
No. years with data
available





E. faecalis Aminopenicillins 7 13-15 0.32 0.24 to 0.39 <0.0001
 High level gentamicin 7 13-15 0.30 0.20 to 0.39 <0.0001
 Vancomycin 7 13-15 0.66 0.62 to 0.70 <0.0001
E. faecium Aminopenicillins 7 13-15 -0.06 -0.21 to 0.10 0.47
 High level gentamicin 7 13-15 0.13 0.03 to 0.22 0.013
 Vancomycin 7 13-15 0.51 0.45 to 0.57 <0.0001
E. coli Aminoglycosides 7 14-15 0.49 0.38 to 0.59 <0.0001
 Aminopenicillins 7 14-15 0.27 0.22 to 0.33 <0.0001




7 14-15 0.43 0.32 to 0.53 <0.0001
 Fluoroquinolones 7 14-15 0.29 0.19 to 0.38 <0.0001
K. pneumoniae Aminoglycosides 5 13-15 0.84 0.75 to 0.93 <0.0001




5 12-15 0.85 0.80 to 0.90 <0.0001
 Fluoroquinolones 5 13-15 0.83 0.73 to 0.92 <0.0001
P. aeruginosa Amikacin 5 9-11 0.83 0.73 to 0.92 <0.0001
 Aminoglycosides 5 11-15 0.89 0.87 to 0.92 <0.0001
 Carbapenems 5 11-15 0.83 0.76 to 0.90 <0.0001
 Ceftazidime 5 11-15 0.82 0.79 to 0.85 <0.0001




5 11-15 0.84 0.78 to 0.90 <0.0001
S. aureus Methicillin 7 15 0.67 0.65 to 0.69 <0.0001
 Rifampicin 7 10-13 0.63 0.56 to 0.69 <0.0001
S. pneumoniae Macrolides 7 12-14 0.86 0.83 to 0.90 <0.0001
 Penicillin 7 12-14 0.45 0.37 to 0.52 <0.0001
doi: 10.1371/journal.pone.0073115.t002
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Strengths of the data analysed in this study include
resistance data, antimicrobial consumption data and inequality
data being collected by single sources: EARS-Net, ESAC and
SWIID, and there being no selection bias in this study as all
EARS-net data were analysed. Limitations of the data are: the
data is only from developed countries within Europe and data
are estimates only. The antimicrobial consumption data used
consisted of total out-patient antibiotic data (all classes
combined), and this study looks at in-hospital bacterial
resistance to specific antibacterials. It has though been shown
that out-patient antibiotic consumption is correlated with in-
patient antibiotic consumption [13] and antimicrobial
consumption for a specific antimicrobial has been related to
resistance to that antimicrobial in previous studies [3]. The
correlations between income inequality and antimicrobial
resistance, seen across all pathogens studied (n=7) and all
antimicrobials (n= 14), are not independent of each other in all
cases. This is principally an issue in E. coli and K. pneumoniae
due to plasmid-mediated resistance, with plasmids carrying
resistance to more than one antimicrobial class [14].
Only correlations are reported in this study and therefore no
causality can be proven. Investigating if causality is present
between inequality and resistance is not possible given the
data only allows us to calculate correlations, though these
correlations reported are consistent with our hypothesis. It is
important to consider if biologically plausible causal
mechanisms support the correlations. Antimicrobial resistance
rates can be increased in two ways. Firstly, exposure to
antimicrobials can create resistance de novo and select out
resistant strains. Secondly, transmission of antimicrobially
resistant bacteria can occur. The associations between income
inequality and antimicrobial consumption, and between
antimicrobial consumption and antimicrobial resistance,
support the former mechanism. In the case of E. faecium-
aminopenicillin resistance, where there is no correlation
between consumption and resistance, as would be expected,
there was still a correlation, albeit weak, between income
inequality and antimicrobial resistance. This would support the
latter mechanism, i.e. that income inequality is involved in
resistance through transmission of resistant bacteria, although
no mediating factor analogous to antimicrobial consumption
has been identified.
To support causality between inequality and consumption,
mediating factors are needed, of which there are many
possibilities. For example, increased income inequality is
associated with higher Body Mass Index (BMI) [5]. Higher BMIs
Figure 1.  Income inequality correlated with vancomycin resistance in Enterococcus faecalis (2003-10).  
doi: 10.1371/journal.pone.0073115.g001
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are associated with comorbidities such as diabetes, resulting in
higher rates of skin infections, caused by S. aureus, and
urinary tract infections, caused by E. coli [15,16]. Co-
morbidities, e.g. obesity, could theoretically result in more
severe infections. However, there is evidence that antimicrobial
consumption varies independently of infection severity [17].
Given this, there could be factors not related to severity that
income inequality impacts upon which affect antibiotic
consumption. For example, increased income inequality is
associated with lower levels of education, and lower
educational levels have been associated with higher rates of
antimicrobial consumption [5,18]. A defined dose of an
antibiotic may also result in varying risks of developing
antibiotic resistance in different countries. For example,
patients with higher BMIs have lower antibiotic concentrations
in the body. These lower concentrations have been implicated
in the development of antibiotic resistance, sub-therapeutic
drug concentrations failing to prevent the emergence of
resistant bacteria [19,20]. Income inequality is also correlated
with factors likely to result in an increased transmission of drug
resistance e.g., imprisonment is associated with community
associated-MRSA and Multi-Drug Resistant Mycobacterium
tuberculosis [5,21,22].
Assuming there is causality between income inequality and
antimicrobial resistance, the mediating factor which seems
likely to be most important is considered to be antimicrobial
consumption. A simple triangular model between inequality-
consumption-resistance may not though reflect reality. As
already demonstrated, E. faecium resistance is correlated with
inequality even though consumption and resistance and not
correlated for this antibiotic. Consideration of the relative
strengths of the correlations also challenges this simple model.
The correlations between income inequality and antimicrobial
resistance are strongest for S. aureus and E. coli. But the
strongest relationships between antimicrobial consumption and
antimicrobial resistance are strongest in K. pneumoniae and P.
aeruginosa. Inequality is likely to act differently on bacteria
depending if they are more commonly community or hospital
pathogens, for example, S. aureus and E. coli are considered
common community pathogens when compared to K.
pneumoniae and P. aeruginosa. Also, consumption affects
different bacteria differently. For example, Klebsiella spp more
easily develop cephalosporin resistance compared to E. coli
due to their chromosomal carriage of B-lactamases [23].
Weak correlations between inequality and resistance were
identified for some pathogen-antimicrobial pairings. The weak
Figure 2.  Income inequality correlated with third generation cephalosporin resistance in Escherichia coli (2003-10).  
doi: 10.1371/journal.pone.0073115.g002
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association between aminopenicillin antimicrobial resistance in
E. faecium with income inequality could be expected, as E.
faecium is commonly resistant to aminopenicillins [24],
whereas all other species are typically susceptible to the
antibiotics they are tested against. S. pneumoniae resistance
has been affected by the introduction of S. pneumoniae
vaccination, causing a replacement of antimicrobial resistance
serotypes of S. pneumoniae [25]. This vaccine effect may have
attenuated links between S. pneumoniae resistance and
income inequality, though no data support this suggestion. For
carbapenems there may be temporal effects present, as these
are the most recently introduced class of antibiotics studied.
The associations described here do not tell us how increased
levels of resistance are distributed within populations as they
are based on population statistics. That is, to suggest these
data allow us to say if resistance is more common in the rich or
poor is not possible. To do so would be to make a statistical
inference error known as the “ecological fallacy”. The
ecological fallacy occurs when statistical data collected about a
group is incorrectly used to make inferences about the nature
of individuals e.g. rich or poor. There is some evidence
available on who may be affected within the population. It may
be that the relatively poor within a society suffer most from
increased antimicrobial resistance as their increased rates of
disease e.g. diabetes, make them prone to more infections
[26]. However, within less equal societies the rich suffer
increased rates of disease compared to the rich within more
equal societies [27]. Therefore, as income inequality increases,
the rich may have relatively high rates of antibiotic resistance.
This association has in fact been shown in a number of studies.
In the USA, households with higher median incomes had
higher rates of infection with penicillin non-susceptible
pneumococci (PNSP) [28]. In Sweden, PNSP have been
positively correlated with antibiotic prescribing, which has been
positively correlated with per capita income [29]. In the USA
study most disease was seen in the relatively poor, but
resistance was higher in the relatively rich. It is likely that
access to healthcare as well as the presence of an infection is
important in the risk of antimicrobial resistance; a study in
Ireland showed patients treated privately were prescribed
antibiotics more often than those treated by the public health
system [30].
The associations between income inequality and
antimicrobial resistance should be considered in the context of
other factors which impact on antimicrobial resistance, e.g.,
culture and practices of prescribers and the public, infection
Figure 3.  Income inequality correlated with quinolone resistance in Klebsiella pneumoniae (2005-10).  
doi: 10.1371/journal.pone.0073115.g003
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control practices, intensity of migration and practices of
antibiotic use in the agricultural sector [31–33]. These factors
may be independently associated with antimicrobial resistance
and potentially income inequality; therefore possible
confounding by income inequality should always be taken into
account in further antibiotic resistance research. It is likely
there is a contribution from numerous factors to a country’s
overall level of antimicrobial resistance and that income
inequality, if causality exists, is one of these factors.
Before undertaking this study, correlations between income
inequality and antimicrobial resistance had not been quantified.
This evidence for a positive association of income inequality
and antimicrobial resistance provides the best information
available at present with which to consider if increasing income
inequality in developed countries does increase antimicrobial
resistance; this should be considered by those researching why
some countries are better at preventing and controlling the
emergence of antimicrobial resistance. To investigate these
associations further requires more data and these may come
from two areas. Firstly, it may be possible to encourage
agencies outside Europe to collect data comparable to that of
the EARS-net, e.g., Centers for Disease Control (U.S.A.) could
complete state-based surveillance. Secondly, it may also be
possible to monitor how the correlation between income
inequality and antimicrobial resistance changes temporally
within a country.
It is important for a country to know what to consider a
normal level of resistance, and using income inequality
correlations may allow this to be achieved. Knowing expected
resistance rates is important as organisational reforms may be
carried out based on crude rates, without consideration of
expected rates. In the UK for example, reforms to the National
Health Service (NHS) have been introduced, one of the
justifications being that the UK had a higher incidence of MRSA
than the European average [34]. If resistance and inequality
are causally related then the UK had MRSA rates consistent
with its level of income inequality and it would be incorrect to
cite past UK MRSA rates in support of reforms to the UKs NHS
[34].
In summary, income inequality in developed European
countries is associated with antimicrobial resistance. These
associations are consistent with a belief that modifying income
inequality within a nation may be an effective public health
intervention to reduce antimicrobial resistance rates.
Figure 4.  Income inequality correlated with methicillin resistance in Staphylococcus aureus (2003-10).  
doi: 10.1371/journal.pone.0073115.g004
Income Inequality and Antimicrobial Resistance
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